Home > Healthcare > Medical Devices > Diagnostic Devices > Thyroid Cancer Diagnostics Market

Thyroid Cancer Diagnostics Market Share

Report ID: GMI9403
Published Date: May 2024
Report Format: PDF

Download Free Sample

Thyroid Cancer Diagnostics Market Share

The thyroid cancer diagnostics sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command significant influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.

Thyroid Cancer Diagnostics Market Companies

Some of the eminent market participants operating in the thyroid cancer diagnostics industry include:

Abbott Laboratories
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
Canon Inc.
Danaher Corporation
Esaote SPA
F. Hoffmann-La Roche Ltd
GE HealthCare
Hologic, Inc.
Illumina, Inc.
Koninklijke Philips N.V.
PerkinElmer, Inc.
Siemens Healthineers AG
Thermo Fisher Scientific Inc.
Veracyte, Inc.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The market size of thyroid cancer diagnostics reached USD 2.9 billion in 2023 and is set to expand at 5.7% CAGR from 2024 to 2032, due to the increasing incidence of thyroid cancer, advancements in diagnostic technologies, and expanding healthcare infrastructure.

The instrument product segment is estimated to reach USD 2.9 billion by 2032, on account of the rising incidence of thyroid cancer globally, coupled with improved screening programs and better healthcare access.

The papillary carcinoma segment of the thyroid cancer diagnostics industry recorded USD 2.3 billion in 2023 and is estimated to register substantial gains through 2032, due to its growing prevalence across the globe.

The U.S. market accounted for USD 1.1 billion in 2023 and is estimated to depict substantial gains between 2024 and 2032, due to robust infrastructure, including a network of well-equipped hospitals, cancer diagnostic centers, and academic institutions.